Recombinant Human EIF1AD Protein, N-His from ProteoGenix; catalogue ARO-P10725; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human EIF1AD Protein, also known as Eukaryotic Translation Initiation Factor 1A Domain Containing Protein, is a recombinant protein that plays an important role in protein synthesis. This protein is a member of the EIF1A family and is encoded by the EIF1AD gene located on chromosome 1 in humans.
The structure of Recombinant Human EIF1AD Protein consists of 129 amino acids with a molecular weight of approximately 14.8 kDa. It contains a conserved N-terminal domain and a C-terminal domain that are connected by a flexible linker region. The N-terminal domain is responsible for binding to the ribosomal subunit, while the C-terminal domain is involved in the regulation of protein synthesis.
Recombinant Human EIF1AD Protein is involved in the initiation stage of protein synthesis, which is the process of translating genetic information from mRNA into proteins. It functions by binding to the small ribosomal subunit, which is responsible for decoding the mRNA sequence. This binding helps to stabilize the ribosomal subunit and promotes the recruitment of other factors necessary for protein synthesis.
In addition, Recombinant Human EIF1AD Protein also plays a role in regulating the fidelity of protein synthesis. It has been shown to interact with other translation factors, such as eukaryotic translation elongation factor 1 alpha (eEF1A), to ensure accurate translation of mRNA into protein.
Recombinant Human EIF1AD Protein has various applications in both research and therapeutic settings. In research, it is commonly used as an antigen for the production of antibodies for studying the structure and function of this protein. It can also be used in in vitro translation assays to study the initiation stage of protein synthesis.
In therapeutic applications, Recombinant Human EIF1AD Protein has shown potential as a target for drug development. It has been found to be overexpressed in certain types of cancer, such as breast and lung cancer, and may play a role in tumor growth and progression. Inhibiting the activity of this protein could potentially lead to the development of new cancer treatments.
Furthermore, Recombinant Human EIF1AD Protein has also been investigated as a potential biomarker for certain diseases. Studies have shown that it is upregulated in patients with Alzheimer’s disease, and its levels can be used to monitor disease progression and response to treatment.
In conclusion, Recombinant Human EIF1AD Protein is a crucial factor in the initiation stage of protein synthesis. Its structure, activity, and potential applications make it a valuable tool in both research and therapeutic settings. Further studies on this protein may lead to a better understanding of its role in various diseases and the development of new treatments.
ProteoGenix catalogue number ARO-P10725. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 16.24 kDa; Fragment: Met1-Gln121; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
